Amyloidosis Treatment Market Size, Share, Trends, Industry Analysis Report: By Treatment, End User, and Region

Description

List of Tables

The global amyloidosis treatment market size is expected to reach USD 9.79 billion by 2032, according to a new study by Polaris Market Research. The report "Amyloidosis Treatment Market Size, Share, Trends, Industry Analysis Report: By Treatment (Chemotherapy, Immunosuppressive Drugs, Transplantation, Supportive Care, Surgery, and Others), End User, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2024-2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The amyloidosis treatment market is a critical segment of the broader healthcare landscape. It focuses on therapies for a rare but serious group of diseases characterized by the abnormal deposition of amyloid proteins in various tissues and organs. Amyloidosis is categorized into several types, including AL (light chain), AA (secondary), hereditary forms, and wild-type ATTR (transthyretin amyloidosis). The complexity of these conditions necessitates a diverse array of treatment options, which has led to significant advancements in the market.

The amyloidosis treatment market has evolved continuously over the decades, driven by a deeper understanding of the disease mechanisms and improved diagnostic techniques. Historically, there were limited treatment options for amyloidosis, often resulting in poor patient outcomes. However, the recent introduction of novel therapies such as daratumumab and tafamidis has transformed the management of this condition.

The global amyloidosis treatment market is expanding due to several factors such as rising awareness, ongoing research and development, and a rising aging population. Moreover, advancements in diagnostic technologies, including imaging and biomarker identification, are facilitating earlier diagnosis, which is crucial for the effective treatment of amyloidosis.

Amyloidosis Treatment Market Report Highlights

Based on end use, the home care settings segment in the amyloidosis treatment market is expected to experience substantial growth during the forecast period due to the rising preference for patient-centered care.

The hospitals & clinics segment dominated the market in 2023 due to their comprehensive infrastructure along with specialized medical staff equipped to handle complex cases of amyloidosis.

By treatment, the chemotherapy segment accounted for a major share of the market in 2023 due to its established efficacy in managing related conditions, particularly AL amyloidosis. Moreover, advancements in combination therapies propelled the demand for chemotherapy.

The transplantation segment is projected to grow at a robust pace during the forecast period owing to the rising recognition of hematopoietic stem cell transplantation for patients affected by AL amyloidosis.

In the global market, North America accounted for the largest revenue share in 2023 due to the rising aging population and increased awareness of the disease.

The market in Asia Pacific is estimated to register a significant CAGR during the forecast period owing to the increasing prevalence of chronic diseases coupled with growing healthcare expenditure.

A few global key market players are Pfizer Inc.; Johnson & Johnson Services, Inc.; GSK plc.; Takeda Pharmaceutical Company Limited; Alnylam Pharmaceuticals, Inc.; Sanofi; Merck KGaA; F. Hoffmann-La Roche Ltd; Novartis AG; Ionis Pharmaceuticals; Bristol-Myers Squibb Company; and Amgen Inc.

Polaris Market Research has segmented the amyloidosis treatment market report based on treatment, end user, and region:

By Treatment Outlook (Revenue, USD Billion, 2024-2032)

Chemotherapy
Immunosuppressive Drugs
Transplantation
Supportive Care
Surgery
Others

By End User Outlook (Revenue, USD Billion, 2024-2032)

Hospitals & Clinics
Ambulatory Surgical Centers
Home Care Settings
Others

By Regional Outlook (Revenue, USD Billion, 2024-2032)

North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Netherlands
Russia
Rest of Europe
Asia Pacific
China
Japan
India
Malaysia
South Korea
Indonesia
Australia
Rest of Asia Pacific
Middle East & Africa
Saudi Arabia
UAE
Israel
South Africa
Rest of Middle East & Africa
Latin America
Mexico
Brazil
Argentina
Rest of Latin America

Product Code: PM5132

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources

4. Global Amyloidosis Treatment Market Insights

4.1. Amyloidosis Treatment Market - Market Snapshot
4.2. Amyloidosis Treatment Market Dynamics
- 4.2.1. Drivers and Opportunities
  - 4.2.1.1. Advancements in diagnostic technologies are driving the market size
  - 4.2.1.2. Increasing clinical trials worldwide are driving the amyloidosis treatment market.
- 4.2.2. Restraints and Challenges
  - 4.2.2.1. The high cost of treatments is expected to impede market growth.
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Amyloidosis Treatment Market Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis

5. Global Amyloidosis Treatment Market, by Treatment

5.1. Key Findings
5.2. Introduction
- 5.2.1. Global Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
5.3. Chemotherapy
- 5.3.1. Global Amyloidosis Treatment Market, by Chemotherapy, by Region, 2019-2032 (USD billion)
5.4. Immunosuppressive Drugs
- 5.4.1. Global Amyloidosis Treatment Market, by Immunosuppressive Drugs, by Region, 2019-2032 (USD billion)
5.5. Transplantation
- 5.5.1. Global Amyloidosis Treatment Market, by Transplantation, by Region, 2019-2032 (USD billion)
5.6. Supportive Care
- 5.6.1. Global Amyloidosis Treatment Market, by Supportive Care, by Region, 2019-2032 (USD billion)
5.7. Surgery
- 5.7.1. Global Amyloidosis Treatment Market, by Surgery, by Region, 2019-2032 (USD billion)
5.8. Others
- 5.8.1. Global Amyloidosis Treatment Market, by Others, by Region, 2019-2032 (USD billion)

6. Global Amyloidosis Treatment Market, by End-use

6.1. Key Findings
6.2. Introduction
- 6.2.1. Global Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
6.3. Hospitals & Clinics
- 6.3.1. Global Amyloidosis Treatment Market, by Hospitals & Clinics, by Region, 2019-2032 (USD billion)
6.4. Ambulatory Surgical Centers
- 6.4.1. Global Amyloidosis Treatment Market, by Ambulatory Surgical Centers, by Region, 2019-2032 (USD billion)
6.5. Home Care Settings
- 6.5.1. Global Amyloidosis Treatment Market, by Home Care Settings, by Region, 2019-2032 (USD billion)
6.6. Others
- 6.6.1. Global Amyloidosis Treatment Market, by Others, by Region, 2019-2032 (USD billion)

7. Global Amyloidosis Treatment Market, by Geography

7.1. Key Findings
7.2. Introduction
- 7.2.1. Amyloidosis Treatment Market Assessment, By Geography, 2019-2032 (USD billion)
7.3. Amyloidosis Treatment Market - North America
- 7.3.1. North America: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
- 7.3.2. North America: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
- 7.3.3. Amyloidosis Treatment Market - U.S.
  - 7.3.3.1. U.S.: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  - 7.3.3.2. U.S.: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
- 7.3.4. Amyloidosis Treatment Market - Canada
  - 7.3.4.1. Canada: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  - 7.3.4.2. Canada: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
7.4. Amyloidosis Treatment Market - Europe
- 7.4.1. Europe: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
- 7.4.2. Europe: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
- 7.4.3. Amyloidosis Treatment Market - UK
  - 7.4.3.1. UK: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  - 7.4.3.2. UK: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
- 7.4.4. Amyloidosis Treatment Market - France
  - 7.4.4.1. France: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  - 7.4.4.2. France: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
- 7.4.5. Amyloidosis Treatment Market - Germany
  - 7.4.5.1. Germany: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  - 7.4.5.2. Germany: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
- 7.4.6. Amyloidosis Treatment Market - Italy
  - 7.4.6.1. Italy: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  - 7.4.6.2. Italy: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
- 7.4.7. Amyloidosis Treatment Market - Spain
  - 7.4.7.1. Spain: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  - 7.4.7.2. Spain: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
- 7.4.8. Amyloidosis Treatment Market - Netherlands
  - 7.4.8.1. Netherlands: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  - 7.4.8.2. Netherlands: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
- 7.4.9. Amyloidosis Treatment Market - Russia
  - 7.4.9.1. Russia: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  - 7.4.9.2. Russia: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
- 7.4.10. Amyloidosis Treatment Market - Rest of Europe
  - 7.4.10.1. Rest of Europe: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  - 7.4.10.2. Rest of Europe: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
7.5. Amyloidosis Treatment Market - Asia Pacific
- 7.5.1. Asia Pacific: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
- 7.5.2. Asia Pacific: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
- 7.5.3. Amyloidosis Treatment Market - China
  - 7.5.3.1. China: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  - 7.5.3.2. China: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
- 7.5.4. Amyloidosis Treatment Market - India
  - 7.5.4.1. India: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  - 7.5.4.2. India: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
- 7.5.5. Amyloidosis Treatment Market - Malaysia
  - 7.5.5.1. Malaysia: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  - 7.5.5.2. Malaysia: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
- 7.5.6. Amyloidosis Treatment Market - Japan
  - 7.5.6.1. Japan: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  - 7.5.6.2. Japan: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
- 7.5.7. Amyloidosis Treatment Market - Indonesia
  - 7.5.7.1. Indonesia: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  - 7.5.7.2. Indonesia: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
- 7.5.8. Amyloidosis Treatment Market - South Korea
  - 7.5.8.1. South Korea: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  - 7.5.8.2. South Korea: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
- 7.5.9. Amyloidosis Treatment Market - Australia
  - 7.5.9.1. Australia: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  - 7.5.9.2. Australia: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
- 7.5.10. Amyloidosis Treatment Market - Rest of Asia Pacific
  - 7.5.10.1. Rest of Asia Pacific: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  - 7.5.10.2. Rest of Asia Pacific: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
7.6. Amyloidosis Treatment Market - Middle East & Africa
- 7.6.1. Middle East & Africa: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
- 7.6.2. Middle East & Africa: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
- 7.6.3. Amyloidosis Treatment Market - Saudi Arabia
  - 7.6.3.1. Saudi Arabia: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  - 7.6.3.2. Saudi Arabia: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
- 7.6.4. Amyloidosis Treatment Market - UAE
  - 7.6.4.1. UAE: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  - 7.6.4.2. UAE: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
- 7.6.5. Amyloidosis Treatment Market - Israel
  - 7.6.5.1. Israel: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  - 7.6.5.2. Israel: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
- 7.6.6. Amyloidosis Treatment Market - South Africa
  - 7.6.6.1. South Africa: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  - 7.6.6.2. South Africa: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
- 7.6.7. Amyloidosis Treatment Market - Rest of Middle East & Africa
  - 7.6.7.1. Rest of Middle East & Africa: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  - 7.6.7.2. Rest of Middle East & Africa: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
7.7. Amyloidosis Treatment Market - Latin America
- 7.7.1. Latin America: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
- 7.7.2. Latin America: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
- 7.7.3. Amyloidosis Treatment Market - Mexico
  - 7.7.3.1. Mexico: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  - 7.7.3.2. Mexico: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
- 7.7.4. Amyloidosis Treatment Market - Brazil
  - 7.7.4.1. Brazil: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  - 7.7.4.2. Brazil: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
- 7.7.5. Amyloidosis Treatment Market - Argentina
  - 7.7.5.1. Argentina: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  - 7.7.5.2. Argentina: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
- 7.7.6. Amyloidosis Treatment Market - Rest of Latin America
  - 7.7.6.1. Rest of Latin America: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  - 7.7.6.2. Rest of Latin America: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)

8. Competitive Landscape

8.1. Expansion and Acquisition Analysis
- 8.1.1. Expansion
- 8.1.2. Acquisitions
8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

9.1. Pfizer Inc.
- 9.1.1. Company Overview
- 9.1.2. Financial Performance
- 9.1.3. Product Benchmarking
- 9.1.4. Recent Development
9.2. Johnson & Johnson Services, Inc.
- 9.2.1. Company Overview
- 9.2.2. Financial Performance
- 9.2.3. Product Benchmarking
- 9.2.4. Recent Development
9.3. GSK plc.
- 9.3.1. Company Overview
- 9.3.2. Financial Performance
- 9.3.3. Product Benchmarking
- 9.3.4. Recent Development
9.4. Takeda Pharmaceutical Company Limited
- 9.4.1. Company Overview
- 9.4.2. Financial Performance
- 9.4.3. Product Benchmarking
- 9.4.4. Recent Development
9.5. Alnylam Pharmaceuticals, Inc.
- 9.5.1. Company Overview
- 9.5.2. Financial Performance
- 9.5.3. Product Benchmarking
- 9.5.4. Recent Development
9.6. Sanofi
- 9.6.1. Company Overview
- 9.6.2. Financial Performance
- 9.6.3. Product Benchmarking
- 9.6.4. Recent Development
9.7. Merck KGaA
- 9.7.1. Company Overview
- 9.7.2. Financial Performance
- 9.7.3. Product Benchmarking
- 9.7.4. Recent Development
9.8. F. Hoffmann-La Roche Ltd
- 9.8.1. Company Overview
- 9.8.2. Financial Performance
- 9.8.3. Product Benchmarking
- 9.8.4. Recent Development
9.9. Novartis AG
- 9.9.1. Company Overview
- 9.9.2. Financial Performance
- 9.9.3. Product Benchmarking
- 9.9.4. Recent Development
9.10. Ionis Pharmaceuticals
- 9.10.1. Company Overview
- 9.10.2. Financial Performance
- 9.10.3. Product Benchmarking
- 9.10.4. Recent Development
9.11. Bristol-Myers Squibb Company
- 9.11.1. Company Overview
- 9.11.2. Financial Performance
- 9.11.3. Product Benchmarking
- 9.11.4. Recent Development
9.12. Amgen Inc.
- 9.12.1. Company Overview
- 9.12.2. Financial Performance
- 9.12.3. Product Benchmarking
- 9.12.4. Recent Development